Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma
The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases...
Gespeichert in:
| Veröffentlicht in: | Frontiers in immunology Jg. 14; S. 1178060 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Frontiers Media S.A
11.10.2023
|
| Schlagworte: | |
| ISSN: | 1664-3224, 1664-3224 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases uniformly express CSPG4. Aiming to prevent off-tumor toxicity while maintaining a high cytolytic potential, we combined a chimeric co-stimulatory receptor (CCR) and a CSPG4-directed second-generation chimeric antigen receptor (CAR) with moderate potency. CCRs are artificial receptors similar to CARs, but lacking the CD3ζ activation element. Thus, T cells expressing solely a CCR, do not induce any cytolytic activity upon target cell binding, but are capable of boosting the CAR T cell response when both CAR and CCR engage their target antigens simultaneously. Here we demonstrate that co-expression of a CCR can significantly enhance the anti-tumor response of CSPG4-CAR T cells
in vitro
as well as
in vivo
. Importantly, this boosting effect was not dependent on co-expression of both CCR- and CAR-target on the very same tumor cell, but was also achieved upon trans activation. Finally, our data support the idea of using a CCR as a powerful tool to enhance the cytolytic potential of CAR T cells, which might open a novel therapeutic window for the treatment of metastatic melanoma. |
|---|---|
| AbstractList | The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases uniformly express CSPG4. Aiming to prevent off-tumor toxicity while maintaining a high cytolytic potential, we combined a chimeric co-stimulatory receptor (CCR) and a CSPG4-directed second-generation chimeric antigen receptor (CAR) with moderate potency. CCRs are artificial receptors similar to CARs, but lacking the CD3ζ activation element. Thus, T cells expressing solely a CCR, do not induce any cytolytic activity upon target cell binding, but are capable of boosting the CAR T cell response when both CAR and CCR engage their target antigens simultaneously. Here we demonstrate that co-expression of a CCR can significantly enhance the anti-tumor response of CSPG4-CAR T cells in vitro as well as in vivo. Importantly, this boosting effect was not dependent on co-expression of both CCR- and CAR-target on the very same tumor cell, but was also achieved upon trans activation. Finally, our data support the idea of using a CCR as a powerful tool to enhance the cytolytic potential of CAR T cells, which might open a novel therapeutic window for the treatment of metastatic melanoma. The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases uniformly express CSPG4. Aiming to prevent off-tumor toxicity while maintaining a high cytolytic potential, we combined a chimeric co-stimulatory receptor (CCR) and a CSPG4-directed second-generation chimeric antigen receptor (CAR) with moderate potency. CCRs are artificial receptors similar to CARs, but lacking the CD3ζ activation element. Thus, T cells expressing solely a CCR, do not induce any cytolytic activity upon target cell binding, but are capable of boosting the CAR T cell response when both CAR and CCR engage their target antigens simultaneously. Here we demonstrate that co-expression of a CCR can significantly enhance the anti-tumor response of CSPG4-CAR T cells in vitro as well as in vivo. Importantly, this boosting effect was not dependent on co-expression of both CCR- and CAR-target on the very same tumor cell, but was also achieved upon trans activation. Finally, our data support the idea of using a CCR as a powerful tool to enhance the cytolytic potential of CAR T cells, which might open a novel therapeutic window for the treatment of metastatic melanoma.The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases uniformly express CSPG4. Aiming to prevent off-tumor toxicity while maintaining a high cytolytic potential, we combined a chimeric co-stimulatory receptor (CCR) and a CSPG4-directed second-generation chimeric antigen receptor (CAR) with moderate potency. CCRs are artificial receptors similar to CARs, but lacking the CD3ζ activation element. Thus, T cells expressing solely a CCR, do not induce any cytolytic activity upon target cell binding, but are capable of boosting the CAR T cell response when both CAR and CCR engage their target antigens simultaneously. Here we demonstrate that co-expression of a CCR can significantly enhance the anti-tumor response of CSPG4-CAR T cells in vitro as well as in vivo. Importantly, this boosting effect was not dependent on co-expression of both CCR- and CAR-target on the very same tumor cell, but was also achieved upon trans activation. Finally, our data support the idea of using a CCR as a powerful tool to enhance the cytolytic potential of CAR T cells, which might open a novel therapeutic window for the treatment of metastatic melanoma. The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases uniformly express CSPG4. Aiming to prevent off-tumor toxicity while maintaining a high cytolytic potential, we combined a chimeric co-stimulatory receptor (CCR) and a CSPG4-directed second-generation chimeric antigen receptor (CAR) with moderate potency. CCRs are artificial receptors similar to CARs, but lacking the CD3ζ activation element. Thus, T cells expressing solely a CCR, do not induce any cytolytic activity upon target cell binding, but are capable of boosting the CAR T cell response when both CAR and CCR engage their target antigens simultaneously. Here we demonstrate that co-expression of a CCR can significantly enhance the anti-tumor response of CSPG4-CAR T cells in vitro as well as in vivo . Importantly, this boosting effect was not dependent on co-expression of both CCR- and CAR-target on the very same tumor cell, but was also achieved upon trans activation. Finally, our data support the idea of using a CCR as a powerful tool to enhance the cytolytic potential of CAR T cells, which might open a novel therapeutic window for the treatment of metastatic melanoma. |
| Author | Lennartz, Simon Kaiser, Andrew Lock, Dominik Teppert, Karin Herbel, Vera Brandes, Caroline Winter, Nora Engert, Fabian Schaser, Thomas |
| AuthorAffiliation | Miltenyi Biotec B.V. & Co. KG , Bergisch Gladbach , Germany |
| AuthorAffiliation_xml | – name: Miltenyi Biotec B.V. & Co. KG , Bergisch Gladbach , Germany |
| Author_xml | – sequence: 1 givenname: Karin surname: Teppert fullname: Teppert, Karin – sequence: 2 givenname: Nora surname: Winter fullname: Winter, Nora – sequence: 3 givenname: Vera surname: Herbel fullname: Herbel, Vera – sequence: 4 givenname: Caroline surname: Brandes fullname: Brandes, Caroline – sequence: 5 givenname: Simon surname: Lennartz fullname: Lennartz, Simon – sequence: 6 givenname: Fabian surname: Engert fullname: Engert, Fabian – sequence: 7 givenname: Andrew surname: Kaiser fullname: Kaiser, Andrew – sequence: 8 givenname: Thomas surname: Schaser fullname: Schaser, Thomas – sequence: 9 givenname: Dominik surname: Lock fullname: Lock, Dominik |
| BookMark | eNp9UcFu1DAQtVCRKKU_wClHLllsj7NxTqgKpVSqVFTgbE2c8eIqjoudReLvcborRDnUF488857fvPeancxxJsbeCr4B0N1750PYbySXsBGi1XzLX7BTsd2qGqRUJ__Ur9h5zve8HNUBQHPKLvsYBj_7eVf1X79cqbq_uKtwHqv-o-R1399VLqZqSYRLoHmpoqsCLZgXXLwt5YRzDPiGvXQ4ZTo_3mfs-6fLb_3n-ub26rq_uKltI-RSW0RhFRFtkbdW25HaQeE4cm2dBDtAAygIXOcU6UYiNV0rxwZa5E6ABThj1wfeMeK9eUg-YPptInrz-BDTzmAqwiYy0ClCtFpxPSoSthtsBwOpjmQnUWHh-nDgetgPgUZbtks4PSF92pn9D7OLv4woBoNsVjXvjgwp_txTXkzw2dJUPKG4z0ZqrYQu8lUZlYdRm2LOidzffwQ3a4jmMUSzhmiOIRaQ_g9k_ep7XPX46TnoHweYpRM |
| CitedBy_id | crossref_primary_10_2183_pjab_100_019 crossref_primary_10_3390_ijms25095023 crossref_primary_10_3390_cancers16193260 crossref_primary_10_1093_hmg_ddae056 |
| Cites_doi | 10.1186/s13045-019-0746-1 10.3390/ijms20235942 10.1186/2051-1426-2-25 10.1158/1078-0432.CCR-13-2218 10.3892/ol.2021.12827 10.1056/NEJMoa1407222 10.1158/2159-8290.CD-21-0407 10.1056/NEJMoa1003466 10.3389/fimmu.2020.622442 10.1038/nbt.2459 10.1002/ijc.2910280307 10.1038/mt.2012.27 10.1096/fj.201801670R 10.1158/0008-5472.CAN-05-1343 10.1080/15384047.2019.1640032 10.1126/scitranslmed.3005930 10.1080/2162402X.2022.2140534 10.1007/s00281-022-00962-4 10.3389/fimmu.2021.780399 10.3389/fimmu.2017.01911 10.1038/cr.2016.142 10.1016/j.imlet.2019.05.003 10.1186/2051-1426-3-S2-P120 10.1080/2162402X.2021.2003532 10.1200/JCO.21.02229 10.3389/fcell.2019.00233 10.1016/j.esmoop.2021.100320 10.1038/mt.2010.24 10.1073/pnas.1009069108 10.1111/j.1755-148X.2011.00929.x 10.18632/oncotarget.437 10.1182/blood-2018-99-112572 10.1126/science.1231143 10.1038/s41590-022-01141-1 10.1038/nm.3838 10.1126/scitranslmed.3008226 10.1200/JCO.2014.56.2736 10.1172/JCI83092 10.1046/j.1365-2990.2002.00412.x 10.3390/cancers14153779 10.1126/scitranslmed.3002842 10.1158/2326-6066.CIR-13-0027 10.1111/j.0022-202X.2005.23798.x 10.1038/s41573-021-00189-2 10.1080/1744666X.2021.1880895 10.3390/cancers11081198 10.1056/NEJMoa1104621 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 Teppert, Winter, Herbel, Brandes, Lennartz, Engert, Kaiser, Schaser and Lock. Copyright © 2023 Teppert, Winter, Herbel, Brandes, Lennartz, Engert, Kaiser, Schaser and Lock 2023 Teppert, Winter, Herbel, Brandes, Lennartz, Engert, Kaiser, Schaser and Lock |
| Copyright_xml | – notice: Copyright © 2023 Teppert, Winter, Herbel, Brandes, Lennartz, Engert, Kaiser, Schaser and Lock. – notice: Copyright © 2023 Teppert, Winter, Herbel, Brandes, Lennartz, Engert, Kaiser, Schaser and Lock 2023 Teppert, Winter, Herbel, Brandes, Lennartz, Engert, Kaiser, Schaser and Lock |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fimmu.2023.1178060 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Open Access: DOAJ - Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-3224 |
| ExternalDocumentID | oai_doaj_org_article_394eaac8408d4e1c9bc93be49e292a4a PMC10603253 10_3389_fimmu_2023_1178060 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM 7X8 5PM |
| ID | FETCH-LOGICAL-c512t-caa1c4eee6a07c8cde7b4add08cf23cb353a1e3f9f4e852ae5972d537a0f13c33 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 4 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001090927100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1664-3224 |
| IngestDate | Fri Oct 03 12:50:36 EDT 2025 Tue Sep 30 17:11:28 EDT 2025 Wed Oct 01 17:11:16 EDT 2025 Tue Nov 18 22:13:35 EST 2025 Sat Nov 29 05:40:35 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c512t-caa1c4eee6a07c8cde7b4add08cf23cb353a1e3f9f4e852ae5972d537a0f13c33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Simon Völkl, University Hospital Erlangen, Germany; Niels Schaft, University Hospital Erlangen, Germany; Theresa L. Whiteside, University of Pittsburgh, United States Edited by: Steven Fiering, Dartmouth College, United States |
| OpenAccessLink | https://doaj.org/article/394eaac8408d4e1c9bc93be49e292a4a |
| PQID | 2884185374 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_394eaac8408d4e1c9bc93be49e292a4a pubmedcentral_primary_oai_pubmedcentral_nih_gov_10603253 proquest_miscellaneous_2884185374 crossref_primary_10_3389_fimmu_2023_1178060 crossref_citationtrail_10_3389_fimmu_2023_1178060 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-10-11 |
| PublicationDateYYYYMMDD | 2023-10-11 |
| PublicationDate_xml | – month: 10 year: 2023 text: 2023-10-11 day: 11 |
| PublicationDecade | 2020 |
| PublicationTitle | Frontiers in immunology |
| PublicationYear | 2023 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Rager (B18) 2022; 14 Liu (B46) 2017; 27 Davila (B2) 2014; 6 Wiesinger (B38) 2019; 11 Wilson (B8) 1981; 28 Long (B35) 2015; 21 Davis (B17) 2019; 20 Zhang (B30) 2019; 7 Geldres (B11) 2014; 20 Robert (B20) 2011; 364 Schlaak (B33) 2012; 3 Pircher (B41) 2015; 3 Hodi (B19) 2010; 363 Tamburini (B14) 2019; 33 Seitz (B28) 2021; 10 Ilieva (B13) 2018; 8 Maude (B1) 2014; 371 Mak (B4) Hou (B5) 2021; 20 Werchau (B15) 2022; 11 SChadendorf (B21) 2015; 33 Beard (B10) 2014; 2 Brentjens (B3) 2013; 5 CheKenya (B12) 2002; 28 Hodi (B27) 2010; 363 Savanur (B39) 2021; 12 Wolchok (B22) 2022; 40 Vergilis (B24) 2005; 125 Price (B48) 2011; 24 Franken (B16) 2021; 6 Kloss (B36) 2013; 31 Bachmann (B29) 2019; 211 Huang (B43) 2022; 23 Morgan (B7) 2010; 18 Wang (B45) 2019; 12 Li (B47) 2018; 132 Wang (B40) 2014; 2 Willsmore (B31) 2020; 11 Yin (B34) 2021; 22 Harrer (B9) 2019; 20 Cherkassky (B44) 2016; 126 Huynh (B6) 2022; 45 Razavi (B23) 2021; 17 Cong (B49) 2013; 339 Kalos (B37) 2011; 3 Adusumilli (B42) 2021; 11 Schmidt (B26) 2011; 108 Pinc (B25) 2012; 20 Fang (B32) 2005; 65 |
| References_xml | – volume: 12 start-page: 59 year: 2019 ident: B45 article-title: Immune checkpoint blockade and CAR-T cell therapy in hematologic Malignancies publication-title: J Hematol Oncol doi: 10.1186/s13045-019-0746-1 – volume: 20 start-page: 5942 year: 2019 ident: B9 article-title: CSPG4 as target for CAR-T-cell therapy of various tumor entities-merits and challenges publication-title: Int J Mol Sci doi: 10.3390/ijms20235942 – volume: 2 start-page: 25 year: 2014 ident: B10 article-title: Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells publication-title: J ImmunoTher Cancer doi: 10.1186/2051-1426-2-25 – volume: 20 year: 2014 ident: B11 article-title: T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-2218 – volume: 22 start-page: 566 year: 2021 ident: B34 article-title: Effect of melanoma stem cells on melanoma metastasis publication-title: Oncol Lett doi: 10.3892/ol.2021.12827 – volume: 371 year: 2014 ident: B1 article-title: Chimeric antigen receptor T cells for sustained remissions in leukemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1407222 – volume: 11 year: 2021 ident: B42 article-title: A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with Malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-21-0407 – volume: 363 year: 2010 ident: B19 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1003466 – volume: 11 year: 2020 ident: B31 article-title: B cells in patients with melanoma: implications for treatment with checkpoint inhibitor antibodies publication-title: Front Immunol doi: 10.3389/fimmu.2020.622442 – volume: 363 year: 2010 ident: B27 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1003466 – volume: 31 year: 2013 ident: B36 article-title: Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells publication-title: Nat Biotechnol doi: 10.1038/nbt.2459 – volume: 28 start-page: 293 year: 1981 ident: B8 article-title: Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies publication-title: Int J Cancer doi: 10.1002/ijc.2910280307 – volume: 20 year: 2012 ident: B25 article-title: Targeting CD20 in melanoma patients at high risk of disease recurrence publication-title: Mol Ther doi: 10.1038/mt.2012.27 – volume: 33 year: 2019 ident: B14 article-title: Structural deciphering of the NG2/CSPG4 proteoglycan multifunctionality publication-title: FASEB J doi: 10.1096/fj.201801670R – volume: 65 year: 2005 ident: B32 article-title: A tumorigenic subpopulation with stem cell properties in melanomas publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-1343 – volume: 20 year: 2019 ident: B17 article-title: Current state of melanoma diagnosis and treatment publication-title: Cancer Biol Ther doi: 10.1080/15384047.2019.1640032 – volume: 5 start-page: 177ra38 year: 2013 ident: B3 article-title: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3005930 – volume-title: Primer to the immune response ident: B4 article-title: Chapter 20 - hematopoietic cancers – volume: 11 start-page: 2140534 year: 2022 ident: B15 article-title: Combined targeting of soluble latent TGF-ß and a solid tumor-associated antigen with adapter CAR T cells publication-title: Oncoimmunology doi: 10.1080/2162402X.2022.2140534 – volume: 45 year: 2022 ident: B6 article-title: Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment publication-title: Semin Immunopathol doi: 10.1007/s00281-022-00962-4 – volume: 12 year: 2021 ident: B39 article-title: Implementing logic gates for safer immunotherapy of cancer publication-title: Front Immunol doi: 10.3389/fimmu.2021.780399 – volume: 8 year: 2018 ident: B13 article-title: Chondroitin sulfate proteoglycan 4 and its potential as an antibody immunotherapy target across different tumor types publication-title: Front Immunol doi: 10.3389/fimmu.2017.01911 – volume: 27 year: 2017 ident: B46 article-title: CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells publication-title: Cell Res doi: 10.1038/cr.2016.142 – volume: 211 start-page: 13 year: 2019 ident: B29 article-title: The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells publication-title: Immunol Lett doi: 10.1016/j.imlet.2019.05.003 – volume: 3 start-page: P120 year: 2015 ident: B41 article-title: FAP-specific re-directed T cells first in-man study in Malignant pleural mesothelioma: experience of the first patient treated publication-title: J Immunother Cancer doi: 10.1186/2051-1426-3-S2-P120 – volume: 10 start-page: 2003532 year: 2021 ident: B28 article-title: Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting publication-title: OncoImmunology doi: 10.1080/2162402X.2021.2003532 – volume: 40 year: 2022 ident: B22 article-title: Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.21.02229 – volume: 7 year: 2019 ident: B30 article-title: Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy. Frontiers in cell and developmental biology publication-title: Front Cell Dev Biol doi: 10.3389/fcell.2019.00233 – volume: 6 start-page: 100320 year: 2021 ident: B16 article-title: Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs publication-title: ESMO Open doi: 10.1016/j.esmoop.2021.100320 – volume: 18 year: 2010 ident: B7 article-title: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 publication-title: Mol Ther doi: 10.1038/mt.2010.24 – volume: 108 year: 2011 ident: B26 article-title: Eradication of melanomas by targeted elimination of a minor subset of tumor cells publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1009069108 – volume: 24 year: 2011 ident: B48 article-title: CSPG4, a potential therapeutic target, facilitates Malignant progression of melanoma publication-title: Pigment Cell melanoma Res doi: 10.1111/j.1755-148X.2011.00929.x – volume: 3 start-page: 22 year: 2012 ident: B33 article-title: Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells publication-title: Oncotarget doi: 10.18632/oncotarget.437 – volume: 132 start-page: 556 year: 2018 ident: B47 article-title: Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia publication-title: Blood doi: 10.1182/blood-2018-99-112572 – volume: 339 year: 2013 ident: B49 article-title: Multiplex genome engineering using CRISPR/Cas systems publication-title: Sci (New York NY) doi: 10.1126/science.1231143 – volume: 23 year: 2022 ident: B43 article-title: A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance publication-title: Nat Immunol doi: 10.1038/s41590-022-01141-1 – volume: 21 year: 2015 ident: B35 article-title: 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors publication-title: Nat Med doi: 10.1038/nm.3838 – volume: 6 start-page: 224ra25 year: 2014 ident: B2 article-title: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3008226 – volume: 33 year: 2015 ident: B21 article-title: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma publication-title: J Clin Oncol: Off J Am Soc Clin Oncol doi: 10.1200/JCO.2014.56.2736 – volume: 126 year: 2016 ident: B44 article-title: Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition publication-title: J Clin Invest doi: 10.1172/JCI83092 – volume: 28 year: 2002 ident: B12 article-title: The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human Malignant brain tumours publication-title: Neuropathol Appl Neurobiol doi: 10.1046/j.1365-2990.2002.00412.x – volume: 14 start-page: 3779 year: 2022 ident: B18 article-title: Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies publication-title: Cancers (Basel) doi: 10.3390/cancers14153779 – volume: 3 start-page: 95ra73 year: 2011 ident: B37 article-title: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3002842 – volume: 2 year: 2014 ident: B40 article-title: Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-13-0027 – volume: 125 year: 2005 ident: B24 article-title: Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma publication-title: J Invest Dermatol doi: 10.1111/j.0022-202X.2005.23798.x – volume: 20 year: 2021 ident: B5 article-title: Navigating CAR-T cells through the solid-tumour microenvironment publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-021-00189-2 – volume: 17 year: 2021 ident: B23 article-title: Chimeric antigen receptor T-cell therapy for melanoma publication-title: Expert Rev Clin Immunol doi: 10.1080/1744666X.2021.1880895 – volume: 11 start-page: 1198 year: 2019 ident: B38 article-title: Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance publication-title: Cancers doi: 10.3390/cancers11081198 – volume: 364 year: 2011 ident: B20 article-title: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1104621 |
| SSID | ssj0000493335 |
| Score | 2.3763611 |
| Snippet | The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin... |
| SourceID | doaj pubmedcentral proquest crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 1178060 |
| SubjectTerms | adoptive T cell therapy chimeric antigen receptor chimeric costimulatory receptor Immunology immunotherapy melanoma |
| Title | Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma |
| URI | https://www.proquest.com/docview/2884185374 https://pubmed.ncbi.nlm.nih.gov/PMC10603253 https://doaj.org/article/394eaac8408d4e1c9bc93be49e292a4a |
| Volume | 14 |
| WOSCitedRecordID | wos001090927100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgAolLxadYCpWRuKHQOONs7GMJWzhAVZUP7c1yJmOxqJtF7S4SF347YyddNhe4cImixFGcN-PMe7I9I8QL0yLZsqSMcIqZVm2RMWvVGbKUCBWVwaftY1_eV6enZj63ZzulvuKasD49cA_cEVhN3iPrENNqUmgbtNCQtlTYwutEjZj17Iipbz3vBYCy3yXDKswehcVyuXkVi4XHeUqTp5yUfyJRStg_YpnjNZI7Qefkrtgf2KI87nt5T9yg7r643deP_PlAzHg0N6nCg6w_nr3VWX18Ln3XyvoNy7W6PpdMSeV2LblcBbmktY-biBbIpxe-Wy39Q_H5ZPapfpcNdREy5PC8ztB7hZqIpj6v0GBLVaP5P5UbDAVgAyV4RRBs0GTKwhOLhqItofJ5UIAAj8Ret-rosZANsE2mxrQKmbppxoUpXwDdsGEVhOlEqGuMHA5Jw2PtigvH4iHi6hKuLuLqBlwn4uX2me99yoy_tn4dod-2jOmu0wV2Ajc4gfuXE0zE82vDOR4ecc7Dd7TaXLnCmJieByo9EWZk0dEbx3e6xdeUaJvlcg5FCU_-Rx8PxJ343THuKfVU7K0vN_RM3MIf68XV5aG4Wc3NYXJiPn74NfsNu6T3vg |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combining+CSPG4-CAR+and+CD20-CCR+for+treatment+of+metastatic+melanoma&rft.jtitle=Frontiers+in+immunology&rft.au=Teppert%2C+Karin&rft.au=Winter%2C+Nora&rft.au=Herbel%2C+Vera&rft.au=Brandes%2C+Caroline&rft.date=2023-10-11&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=14&rft.spage=1178060&rft_id=info:doi/10.3389%2Ffimmu.2023.1178060&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |